Topical spironolactone, spironolactone applied to the skin, has very limited evidence for teens with inflammatory acne, red and tender papules and pustules. The Journal of Clinical and Aesthetic Dermatology review found six small studies with 193 treated patients, mostly females aged 11 to 40, leaving teen males little studied the 2026 review. An Italian dermatology journal reported 48 adolescent girls aged 13 to 17 using 5% cream twice daily for 24 months. Different formulas and conflicting results make it hard to choose a teen dose from these data.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What did the six studies test?
- Who was studied and who was not?
- Did it change inflammatory breakouts?
- What should teens discuss with a dermatologist?
What did the six studies test?
The review covered 5% cream, 5% gel, 2% solution and 1% nanogel. Most were small randomized trials. The Journal of Clinical and Aesthetic Dermatology describes limited efficacy and safety data with some conflicting results across them the review methods and findings.
That mix prevents direct comparison of one strength or base. A result with 5% cream does not predict a result with 2% solution. Read any single-study claim against that fragmented base.
Who was studied and who was not?
The pooled group spanned ages 11 to 40. It included 152 women out of 195 patients, according to the Journal of Clinical and Aesthetic Dermatology summary of the Rehan review. Teen males, children under 11 to 12, and older males were little studied.
Only one study focused on teens. An Italian dermatology journal reported 48 adolescent women aged 13 to 17 with acne vulgaris used 5% cream twice daily for 24 months. No teen study centered on boys.
- Studied: females 11 to 40, including 48 girls 13 to 17 in one long cream study
- Little studied: teen males, children under 11 to 12, older males
Did it change inflammatory breakouts?
Topical spironolactone reduced papules, closed comedones and total counts versus placebo, the Journal of Dermatology reported the Wiley trial summary. The same source reported 2% solution reduced comedones, papules, pustules and a severity index versus clindamycin.
Papules are small red bumps, pustules hold visible pus, and closed comedones are clogged pores under skin. Lower counts do not equal clear skin for every teen. Small size and conflicting results limit confidence for severe inflammatory acne.
What should teens discuss with a dermatologist?
The strongest oral-spironolactone trial, SAFA, enrolled only women 18 or older with persistent facial acne warranting oral antibiotics, the BMJ trial report states the SAFA trial report. Adolescents were explicitly excluded. By contrast, clascoterone 1% cream received FDA approval in August 2020 for acne vulgaris in patients 12 and older, according to the DailyMed label the DailyMed label. The label describes two Phase III trials totaling 1,440 patients that included teens of both sexes.
Topical spironolactone and flutamide are not FDA-approved. They must be compounded extemporaneously with no supporting pharmacokinetic data, according to the Journal of Clinical and Aesthetic Dermatology review. That means no standardized teen dose, safety or access pathway exists. Bring the age, sex and severity gaps to the visit and ask about approved options for inflammatory lesions at 13 to 17.
You Might Also Like
- Topical Hormonal Acne Treatments in a 2026 Review: Who Was Studied and Who Was Not for Teens With Inflammatory Acne
- Topical Clascoterone Evidence Revisited in 2026: Who Was Studied and Who Was Not for Teens With Inflammatory Acne
- Limited Topical Spironolactone Evidence in the 2026 Review: How Teens With Inflammatory Acne Can Avoid Overreading the Headline